Tracheal localization of inflammatory myofibroblastic tumor in adults: A case report

  • Branislav Oluić Clinical Center of Serbia, Emergency Center, Belgrade, Serbia
  • Radomir Vešović Clinical Center of Serbia, Clinic for Thoracic Surgery, Belgrade, Serbia
  • Zlatibor Lončar University of Belgrade, Faculty of Medicine, Belgrade, Serbia
  • Jelena Stojšić Clinical Center of Serbia, Service of Histopathology, Belgrade, Serbia
  • Nataša Mujović Faculty of Medicine, Belgrade, Serbia
  • Dejan Nikolić Faculty of Medicine, Belgrade, Serbia
Keywords: diagnosis;, immunohistochemistry;, inflammation;, surgical procedures, operative;, thoracotomy;, tracheal neoplasms.

Abstract


Introduction: Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm. This disease, of unknown etiology, runs an unpredictable course. Its definitive diagnosis calls for detailed histopathological analysis including immunohistochemistry. Microscopically, IMT is composed of myofibroblastic spindle and inflammatory cells in different proportions. It presents infrequently in adults with nonspecific symptomatology. The presence of IMT is described in every anatomical region but the tracheal one is especially uncommon.

Case report: A 41-year-old female patient checked into our institution due to exacerbation of asthma-like symptoms such as shortness of breath, cough and exertion intolerance. She was originally treated as asthmatic patient with bronchodilator therapy with no success. Chest x-ray done during one of outpatient follow-up appointments pointed to a suspected change in the tracheal distal part. After her admission to our institution, the following diagnostic procedures were performed, spirometry, chest computerized tomography (CT) scan, chest magnetic resonance imaging (MRI) and bronchoscopy and the change in tracheal distal third was confirmed. Right sided thoracotomy with mobilization of lung, tracheal resection and termino-terminal (T-T) anastomosis was undertaken. Subsequent histopathological analysis of surgically removed afflicted tracheal part including immunohistochemistry enabled us to definitively diagnose IMT. Four years after surgical resection, patient shows no recidivism of illness.

Conclusion: Definitive IMT diagnosis requires detailed diagnostic tests, most importantly, an adequate histopathological analysis including immunohistochemistry. Complete surgical resection is the treatment of choice in case of IMT. Further monitoring of patients is necessary due to risk of recurrence.

References

REFERENCES:

Cerfolio RJ, Allen MS, Nascimento AG, Deschamps C, Trastek VF, Miller DL, et al. Inflammatory pseudotumors of the lung. Ann Thorac Surg 1999; 67(4): 933–6.

Fletcher CD, Unni KK, Mertens F. Pathology and genetics of tu-mours of soft tissue and bone. World Health Organization classification of tumours. Lyon (France): IARC Press; 2006.

De Palma A, Loizzi D, Sollitto F, Loizzi M. Surgical treatment of a rare case of tracheal inflammatory pseudotumor in pediat-ric age. Inter¬act Cardiovasc Thorac Surg 2009; 9(6): 1035–7.

Vivero RJ, Dave SP, Roy S. Inflammatory pseudotumor of the tra¬chea. Int J Pediatr Otorhinolaryngol Extra 2006; 1(3): 217–9.

Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, et al. Crizotinib inALK-rearranged inflamma-tory myofibro¬blastic tumor. N Engl J Med 2010; 363(18): 1727–33.

Gaissert HA, Grillo HC, Shadmehr BM, Wright CD, Gokhale M, Wain JC, et al. Uncommon primary tracheal tumors. Ann Tho¬rac Surg 2006; 82(1): 268–72; discussion 272–3.

Fabre D, Fadel E, Singhal S, de Montpreville V, Mussot S, Mercier O, et al. Complete resection of pulmonary inflammatory pseudo¬tumors has excellent long-term prognosis. J Thorac Cardiovasc Surg 2009; 137(2): 435–40.

Oztuna F, Pehlivanlar M, Abul Y, Tekinbas C, Ozoran Y, Ozlu T. Adult inflammatory myofibroblastic tumor of the trachea: Case report and literature review. Respir Care 2013; 58: e72–6.

Matsubara O, Tan-Liu NS, Kenney RM, Mark EJ. Inflammatory pseudotumors of the lung: Progression from organizing pneu-monia to fibrous histiocytoma or to plasma cell granu¬loma in 32 cases. Hum Pathol 1988; 19(7): 807–14.

Venizelos I, Papathomas T, Anagnostou E, Tsanakas J, Kirvassilis F, Kontzoglou G. Pediatric inflammatory myofibroblastic tumor of the trachea: a case report and review of the literature. Pedi-atric Pulmonology 2008; 43(8): 831–5.

Mondello B, Lentini S, Barone M, Barresi P, Monaco F, Familiari D, et al. Surgical management of pulmonary inflammatory pseudotumors: A single center experience. J Cardiothorac Surg 2011; 6: 18.

Bumber Z, Jurlina M, Manojlović S, Jakić-Razumović J. Inflamma-tory pseudotumor of the trachea. J Pediatr Surg 2001; 36(4): 631‒4.

Alam M, Morehead RS, Weinstein MH. Dermatomyositis as a presentation of pulmonary inflammatory pseudotumor (Myo-fibroblastic tumor). Chest 2000; 117(6): 1793‒5.

Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization Classification of Tumours. Pa-thology and Genetics of Tumours of the Lung, Pleura, Thy-mus and Heart. Lyon: IARC Press; 2004.

Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura. Lyon: Thymus and Heart; 2015.

Cessna MH, Zhou H, Sanger WG, Perkins SL, Tripp S, Pickering D, et al. Expression of ALK1 and p80 in inflammatory myo-fibroblastic tumor and its mesenchymal mimics: A study of 135 cases. Mod Pathol 2002; 15(9): 931‒8.

Doski JJ, Priebe CJ, Driessnack M, Smith T, Kane P, Romero J. Corticosteroids in the management of unresected plasma cell granuloma (inflammatory pseudotumor) of the lung. J Pediatr Surg 1991; 26(9): 1064‒6.

Bando T, Fujimura M, Noda Y, Hirose J, Ohta G, Matsuda T. Pulmonary plasma cell granuloma improves with corticoster-oid therapy. Chest 1994; 105(5): 1574‒5.

Panagiotopoulos N, Patrini D, Gvinianidze L, Woo WL, Borg E, Lawrence D. Inflammatory myofibroblastic tumour of the lung: a reactive lesion or a true neoplasm? J Thorac Dis 2015; 7(5): 908‒11.

Published
2021/02/10
Section
Case report